Catheter-based percutaneous transluminal gene delivery (PTGD) into the coronary artery still falls behind the expectations of an efficient myocardial gene delivery system. In this study gene delivery was applied by selective pressureregulated retroinfusion through the coronary veins to prolong adhesion of replication defective adenovirus within the targeted myocardium. Adenoviral vectors consisted either of luciferase (Ad.rsv-Luc) or ␤-galactosidase (Ad.rsv-␤Gal) reporter gene under control of an unspecific promotor derived from the Rous sarcoma virus (RSV). In this pig model, selective retrograde gene delivery into the anterior cardiac vein during a brief period of ischemia substantially
Introduction
Myocardial gene transfer mediated by replicationdeficient adenoviral vectors has been the most successful approach so far to introduce foreign DNA into heart cells in experimental models. [1] [2] [3] [4] [5] In larger animals such as the pig, however, significant transfection and reporter gene expression was only reached by direct injection of the adenoviral vectors into the myocardium 2, 6 or by using local delivery devices for gene transfer into the wall of coronary arteries such as porous or double balloon catheters. 3, 7 A regional and more homogeneous myocardial gene transfer, however, might be a prerequisite for gene delivery strategies targeted to influence myocardial contractility or regional myocardial blood supply. Previous attempts at percutaneous transluminal gene delivery (PTGD) have included systemic intravenous and intraarterial injections. 6, 8, 9 Direct delivery of adenoviral vectors into coronary arteries resulted in relatively low myocardial gene expression in a canine model. 6 For efficient gene transfer high viral titers were required carrying the worrying risk of undesired effects in tissues other than the myocardium. An alternative catheter-based gene delivery device using pericardial application of adenoviral vectors limited systemic contamination. However, gene expression was restricted to the parietal and visceral increased reporter gene expression in the targeted myocardium (LAD region) compared with antegrade delivery as a control. Repeated retrograde delivery during two periods of brief ischemia resulted in a more homogeneous transmural expression predominantly observed in cardiomyocytes (Xgal-staining). In the nontargeted myocardium (CX region) there was no evidence for adenoviral transfection. From our data we infer that selective pressure-regulated retroinfusion is a promising approach for efficient percutaneous transluminal gene delivery to the myocardium. Gene Therapy (2000) 7, 232-240.
pericardium. 10, 11 Although some focal areas of the epicardium were reached after pretreatment with doxycyclin, 11 the pericardial approach does not yet seem to be sufficient to provide myocardial gene expression with homogeneous transmural distribution.
Apparently, one of the major limitations of intravascular delivery for myocardial gene tranfer in larger animals, in contrast to tissue culture systems, 4, 12, 13 is the short adhesion time of adenoviral vectors with endothelial cells and cardiomyocytes. Prolongation of the viral adhesion time as shown by intramyocardial injections and local gene delivery into the wall of coronary arteries substantially increased transfection and gene expression. 2, 3, 6 In order to solve this limitation of intra-arterial gene delivery, we sought to develop a novel approach of percutaneous transluminal retrograde gene delivery (PTRGD) through the coronary veins.
Selective retroinfusion of coronary veins has been previously shown to enhance myocardial concentration of ␤-blockers and calcium antagonists in ischemic myocardium. [14] [15] [16] More recently, we could demonstrate that pressure-regulated retroinfusion was able to target dobutamine selectively to the ischemic myocardium without systemic effects. 17 Similar results were obtained in patients undergoing retroinfusion supported high risk PTCA or stent implantation. 18 Hence, efficacious regional drug delivery was observed by means of selective retroinfusion to ischemic myocardium. With the aim of retrograde adenovirus-mediated gene delivery a modified technique using continuous pressure-regulated retroinfusion was applied based on the assumption that adhesion of the adenoviral vectors can be improved by pressureregulated retroinfusion of coronary veins.
Using this novel approach of myocardial gene delivery by retroinfusion, we here demonstrate that adenoviral gene transfer to ischemic myocardium was substantially increased compared with transluminal antegrade delivery, thereby offering a promising new approach for myocardial gene transfer.
Results
In order to optimize percutaneous transluminal adenoviral gene delivery, antegrade intracoronary and retrograde coronary venous delivery with and without ischemia were compared in five experimental groups in this study ( Figure 1 ).
Adenoviral gene delivery into coronary arteries with and without ischemia
Previous studies in larger animals using adenoviral vectors for gene delivery into coronary arteries without ischemia demonstrated negligible levels of gene expression. 6 To test whether ischemia can increase viral transfection, antegrade intracoronary delivery was performed with (group A, n = 5) and without ischemia (group B, n = 5) in this study. Despite delivery during ischemia (group B) there was only a nonsignificant increase in luciferase activity (159 ± 156 versus 56 ± 73 RLU/mg protein) (Figure 2 ).
Selective retrograde application into coronary veins with and without ischemia
In order to test whether retrograde gene delivery can increase viral transfection, the viral vectors were applied Gene Therapy through the anterior cardiac vein using pressure-regulated retroinfusion in groups C, D and E (Figure 1 ).
Without ischemia, retrograde delivery (group C, n = 5) did not result in an increase of reporter gene expression ( Figure 2 ). However, if applied during ischemia (group D, n = 5), retrograde delivery substantially increased mean reporter gene expression in the LAD region (23 425 ± 25 238 RLU/mg protein) (P Ͻ 0.001) compared with antegrade delivery during ischemia (Figure 2 ). Apparently, retrograde gene transfer was selectively targeted to the LAD region because luciferase activity was at background level in the CX region (61 ± 50 RLU/mg protein, Figure 2) .
Analysis of the distribution of reporter gene expression in the targeted LAD region showed that there was high luciferase activity in the proximal and middle LAD region after retrograde delivery during 10 min of ischemia ( Figure 3 ). However, gene transfer into the myocardium corresponding to the distal LAD region was less effective. With the aim of further enhancing retrograde gene transfer in the whole LAD region, two retrograde administrations of the viral vectors were performed during two ischemic periods of 10 min in group E (n = 5). Reperfusion of 30 min between the two ischemic periods of 10 min was chosen to exclude myocardial infarction in this pig model which may occur after 20 min of continuous ischemia. Using two retrograde treatments and thereby doubling the total amount of adenoviral vector delivery (4.0-5.0 × 10 9 p.f.u.) resulted in approximately twice the luciferase activity (55 010 ± 40 926 RLU/mg protein, Figure 2) and endocardial probes (28 856 ± 20 847 RLU/mg protein) (P Ͻ 0.001) and still considerable heterogeneity, reporter gene expression was more equally distributed throughout the LAD region than after a single retrograde delivery ( Figure 3 ).
Comparison of passage time
In order roughly to estimate whether the passage time of the adenoviral vectors within the coronary microcirculation can be prolonged using the different modes of delivery, the passage time of contrast agent was determined. Whereas similar passage times were observed using antegrade delivery with (0.8 ± 0.4 s) and without ischemia (0.7 ± 0.5 s), retrograde delivery during ischemia significantly increased passage time to 9.5 ± 2.5 s. During retrograde delivery without ischemia the contrast agent appeared in the larger coronary veins distal to the retroinfusion catheter and was washed out by antegrade blood flow within 7 ± 4.5 s. However, no passage of the contrast agent through the microvasculature was observed during retrograde delivery without ischemia which is in agreement with previous observations in pigs 19 and humans. Gene Therapy detection of efficient adenoviral gene transfer using both reporter genes argues against false positive ␤-galactosidase staining due to microinfarctions. 20 Furthermore, there was no evidence for microinfarctions in these probes by histological assessment.
Semiquantitative analysis showed that 15-25% of the cardiomyocytes were positively stained. Although ␤-galactosidase staining might have underestimated the amount of transfected cardiomyocytes, myocardial distribution of positive cardiomycytes determined 7 days after gene delivery was relatively inhomogenous in the transmyocardial sections. Adjacent to clusters of positively staining cells, myocardial tissue with single positive (Figure 4b ) or only negative staining cardiomyocytes were found. Thus, the higher resolution of histological assessment revealed inhomogenous distribution of ␤-galactosidase expression despite relative homogenous luciferase expression in the probes of epicardial, midmyocardial or endocardial origin (Figure 3 ).
Immunohistochemistry
The well known immune response to first generation adenoviral vectors 2 was obviously present 7 days after retrograde gene transfer ( Figure 5 ). Cytolysis of cardiomyocytes was seen in areas massively infiltrated by populations of small spherical cells containing prominent nuclei, which were CD3-positive cells. In other areas, the presence of fibroblasts and only a few CD3-positive lymphocytes suggested an immune response in a later stage. Interestingly, the clusters of cardiomyocytes and CD3-positive T cells were predominantly distributed along the veins and venoles ( Figure 5 ) whereas this phenomenon was not seen in the vicinity of arteries and arterioles.
Transfection of noncardiac tissues
In order to evaluate noncardiac adenoviral transfection or reporter gene expression, PCR for the adenoviral sequences and determination of luciferase activity was performed in several other tissues. Using both detection methods there was no evidence for transfection of other organs than the heart. Selectivity of gene transfer to the LAD region was confirmed by the observation that PCR for adenoviral sequences was negative for all probes of the control region (circumflex artery) in contrast to the LAD probes ( Figure 6 ). 
Discussion
The purpose of this study was to characterize the efficacy and selectivity of a new percutaneous transluminal retrograde gene delivery system (PTRGD). Selective pressureregulated retroinfusion of coronary veins provides a unique access to ischemic myocardium in patients 18 regardless of occluded or diffusely stenotic coronary arteries. Based on previous observations that myocardial concentrations of different drugs could be substantially increased by retroinfusion without systemic effects, 17, 18 this delivery system was used for the first time to transfer reporter genes into ischemic myocardium. The concept of prolonging adhesion of the adenoviral vectors by pressure-regulated retroinfusion in this study was supported by the observation that the passage time of contrast agent through ischemic myocardium could be increased more than 10-fold compared with antegrade delivery. Probably due to the prolonged passage of time, transfection rates and thus, reporter gene expression substantially increased if the adenoviral vectors were delivered by pressure-regulated retroinfusion during ischemia (groups D and E, Figures 2 and 3) . In contrast, luciferase expression did not significantly increase after antegrade delivery during ischemia (group B, Figure 2 ) indicating that retrograde delivery was essential for improving myocardial gene transfer during ischemia. Furthermore, reporter gene expression was increased throughout all myocardial layers in the LAD region after retrograde delivery (Figure 3) . However, two treatment periods with doubling of the total amount of adenoviral vectors at the same time were necessary to obtain a rather homogeneous distribution (Figure 3) . Nevertheless, relatively low virus titers in relation to the size of the heart were used in this pig model if compared with studies in smaller animals with the application of the same amounts of the same adenoviral vector. In all pigs treated by retrograde gene delivery during ischemia, a significant gradient in gene expression from the epicardial to endocardial layers was observed ( Figure  3 ). These findings are consistent with previous observations that an epicardial to endocardial gradient exists if drugs are delivered to the myocardium through the coronary veins. [14] [15] [16] Transfection efficacy may be influenced by modifications of the retroinfusion fluid. Although physiological temperature and the use of cristalloid solution as opposed to whole blood 21 for retroinfusion was taken into account in this study, transfection efficacy might be further enhanced by drugs such as serotonin, bradykinin or L-NAME as demonstrated in isolated rabbit hearts. 22 With regard to regional myocardial delivery of these substances, 23 selective retroinfusion of coronary veins cer- Gene Therapy tainly has the potential to combine adenoviral vector application with regional drug delivery. An important issue for the safety of any catheter-based regional myocardial gene delivery system is the nontargeted transfection of either the heart or other organs. Although we examined myocardial probes from different sites and different layers of the circumflex region, there was no evidence for reporter gene expression by luciferase assay or by histochemical assessment for ␤-galactosidase expression. In addition, PCR for the adenovirus was clearly positive in the LAD (Figure 6 ) but in none of the specimens obtained from the circumflex region, suggesting that gene vector delivery by pressure-regulated retroinfusion was indeed restricted to the targeted LAD region. Furthermore, there was no transfection detected by PCR in other organs, particularly not in the liver, indicating at least only limited systemic contamination by the adenoviral vectors. The use of continuous pressure regulation to adapt retroinfusion to the individual coronary venous systems 17 may reduce but certainly cannot eliminate systemic delivery of retroinfusion fluid by venovenous and venoarterial shunts. Our data, however, suggest that most of the adenoviral vectors attached and entered the myocardium of the LAD region through the coronary veins and venoles ( Figure 5 ) during regional delivery by selective retroinfusion. Nevertheless, we cannot exclude systemic contamination through venovenous or venoarterial shunts because the sensitivity of the detection methods for the adenovirus may underestimate nontargeted adenoviral transfection. Nontargeted transfection may be excluded by the use of the cardio-specific myosin light chain 2 promotor, which is, however, associated with lower gene expression rates. 5, 13, 24, 25 In order to provide cardio-specific and efficient gene transfer at the same time, retrograde delivery of adenoviral vectors under the control of the myosin light chain 2 promotor is currently under investigation in our pig model.
Another limitation of the present study was the use of a first generation adenovirus which is known to induce a severe immunoresponse after transfection. 2, 3 In this study we did not aim to improve the gene vector itself.
Therefore, an established adenoviral vector of the first generation was applied, which has previously been shown to provide high transfection rates in cell cultures as well as in small animals. 2, 5, 13 The time-course of gene expression after adenoviral transfection was also taken into account for determination of reporter gene expression 7 days after gene delivery. 2, 6 Consistent with previous reports 2, 6 we also observed massive lymphocellular infiltration 7 days after transfection in the LAD probes with positive staining for ␤-galactosidase expression. Interestingly, lymphocellular infiltration was predominantly present along the cardiac veins and venoles ( Figure 5) , which was not reported in studies using intramyocardial injection of adenoviral vectors. 2, 6 These data provide further evidence of efficient transvascular adenoviral transfection through the cardiac veins and venoles by continuous selective pressure-regulated retroinfusion, but at the expense of a distinct immunoresponse. Future studies will need to address whether new generations of adenoviral vectors [26] [27] [28] can be transfected by selective retroinfusion with the same efficacy but without or with less immunoresponse.
In summary, this new percutaneous transluminal retrograde gene delivery (PTRGD) using pressure-regulated selective retroinfusion of coronary veins is a promising approach for efficient regional gene delivery in the upcoming era of therapeutic angiogenesis and myocardial gene therapy.
7,28,29

Materials and methods
The present investigation was carried out according to the 'Guide for the Care and Use of Laboratory Animals' published by the US National Institutes of Health and was approved by the Bavarian Animal Care and Use Committee.
Twenty-five German farm pigs (mean body weight 24 ± 4 kg) were anaesthetized by injection of 500 mg ketamine (Parke-Davis, Freiburg, Germany), 0.35 mg/kg body weight midazolam (Roche, Grenzach-Whylen, Switzerland) and 0.5 mg atropine (Braun, Melsungen, Germany). Anaesthesia was maintained by 10 mg/h midazolam intravenously, 10 mg/h piritramide intravenously (Janssen, Neuss, Germany) and ethrane 1-1.5% (Abbott, Chicago, IL, USA). Following endotracheal intubation, arterial pO 2 was kept between 100 and 180 mmHg and expiratory CO 2 concentration at 4.5% by mechanical ventilation.
Catheter introducer sheaths were placed in the right carotid artery (8F, Cordis, Miami, FL, USA) and right external jugular vein (8.5F, Arrows, Reading, MA, USA). Arterial blood pressure was continuously monitored and intravenous anaesthetics, antibiotics (vancomycin 1 g as single bolus injection) as well as fluids were given through the sideport of the venous sheath. Full anticoagulation was achieved by bolus injection of heparine 20 000 IU before catherization followed by continuous application of 5000 IE/h.
At the end of the first experiment (day 0) all catheters and introducer sheaths were removed, the vessels ligated and the wound surgically closed. Anaesthesia was stopped and after 30-60 min the pig was extubated and thereafter brought to the cage.
Seven days later the animal was again anaesthetized, intubated and catheter introducer sheats were placed as decribed above. The patency of the left anterior descending artery was confirmed by coronary angiography. Thereafter, the animal was killed and the heart was excised. Representative probes of the lung, the liver, the kidney, the spleen and in selected animals of the brain were obtained.
Catherization procedures
In all animals a 7F guiding catheter (Cordis) was placed in the left coronary artery. For selective delivery of adenoviral vectors into the left anterior descending artery after the first diagonal branch a 3.0 mm 'over the wire' PTCA balloon was used. In the case of ischemia (groups B, D, E, Figure 1) , the left anterior descending artery was stented (16 mm PUVA, Devon, Germany) because previous studies showed that acute occlusions of the artery due to dissection after balloon inflation could be avoided in the follow-up period of up to 14 days. 30 During ischemia complete occlusion of the LAD artery by balloon inflation (6-8 atm) was verified by angiography.
In pigs treated by selective retroinfusion, the anterior interventricular vein was selectively catherized through the coronary sinus and the great cardiac vein using a 6F retroinfusion catheter as described previously. 17 Continuous selective pressure-regulated retroinfusion The system of selective suction and pressure-regulated retroinfusion has been described in detail elsewhere. [17] [18] [19] For regional application of adenoviral vectors a modified technique of continuous pressure-regulated retroinfusion was used operating in an untriggered mode and with inactivation of the suction device. Therefore, two of the four lumens of the retroinfusion catheter were connected to the high pressure reservoir (2.5 atm) filled with saline solution (0.9%) which was kept at 37°C. The adenoviral vector solution was added to the retroinfusion line immediately after the high pressure reservoir through a stopcock valve. The third lumen of the retroinfusion catheter was used for continous monitoring of the coronary venous pressure. The fourth lumen was used to inflate the balloon at the tip of the retroinfusion catheter.
Before retroinfusion the systolic plateau of coronary venous occlusion pressure was determined by a 20 s balloon occlusion of the coronary vein without ischemia. The preset retroinfusion pressure was chosen 20 mmHg higher than the systolic plateau of coronary venous occlusion pressure thereby allowing adaptation of selective retroinfusion to the individual coronary venous system as described previously. 17 With the start of continuous selective pressure-regulated retroinfusion (Figure 1) , the balloon at the tip of the retroinfusion catheter was inflated to a pressure of 150 mmHg, which was maintained constantly during the retroinfusion treatment. The excenter valve was then opened providing retrograde delivery of the saline solution together with the added adenoviral vectors driven by the high pressure in the reservoir until the preset retroinfusion pressure was reached in the coronary vein. Thereafter, retrograde flow was regulated within milliseconds by the excenter valve to adjust coronary venous pressure to the preset value during continuous retroinfusion ( Figure 7) .
Determination of passage time of contrast agent
In order to estimate roughly passage time of the adenoviral solution after antegrade or retrograde delivery, con-trast agent (1 ml) was added as a bolus injection to the infusion line of the catheter at the end of each treatment period. Using video monitoring, the appearance of the contrast agent in the coronary artery or coronary vein as well as the disappearance through the microvasculature was determined three times during each mode of delivery.
Preparation of adenoviral vectors
Recombinant viruses were constructed by homologous recombination between plasmids pAd.rsv-Luc, pAd.rsv␤Gal and ClaI digested adenoviral DNA of Addel324 in HEK-293 cells as described in detail previously. 13 Before application DNA of the viral stocks was chararacterized by restriction enzyme analysis and wild-type Ad-5 contamination was excluded by PCR. 5, 13 For catheter-based application of the recombinant adenovirus (Ad.rsv-Luc, Ad.rsv-␤Gal) 20 l of viral stock (2.0-2.5 × 10 9 p.f.u.) were diluted in 25 ml of saline (0.9%) immediately before delivery.
Experimental groups
Five experimental groups (A-E) were designed ( Figure  1 ). In group A (n = 5) the adenoviral vectors (2.0-2.5 × 10 9 p.f.u.) were administered into the LAD artery without ischemia. During 10 min of ischemia in group B (n = 5), the adenoviral vectors (2.0-2.5 × 10 9 p.f.u.) were given continuously through the lumen of the 'over the wire' balloon catheter using a constant infusion rate of 2.5 ml/min. The same concentration of the viral vectors diluted in 25 ml of saline solution (0.9%) and the same infusion rate was applied in groups C (n = 5) and D (n = 5). However, the viral vectors were supplied to the infusion line connected to the retroinfusion catheter. Thus, the viral vectors were given retrogradely into the coronary veins draining the LAD region by continuous selective pressure-regulated retroinfusion (Figure 1 ). Retrograde delivery without ischemia (group C) was compared with delivery during 10 min of ischemia (group D). In group E (n = 5) two periods of 10 min ischemia were interrupted by 30 min of reperfusion in order to avoid myocardial infarction in this pig model. During each ischemic period the viral vectors were delivered by retroinfusion (total amount of 4.0-5.0 × 10 9 p.f.u.). In two animals of each group, adenoviral vectors encoding for the nuclear-localizing ␤-galactosidase (2.0-2.5 × 10 9 p.f.u.) were simultaneously administered with the vectors encoding for the luciferase reporter gene.
Luciferase assay
Seven days after application of the viral vectors, the heart of each animal was removed and placed in ice-cold PBS. Transmural cylindrical cores 1 cm in diameter were obtained at different places in the LAD region and in the CX region as a control (Figure 1 ). Each cylindrical core was first divided into two equal transmural half-cores. One half-core was then divided further into three equal pieces of endocardial, midmyocardial and epicardial myocardium. Each sample was shock frozen (−70°C) until assessment of luciferase activity. After mincing for homogenization in lysis buffer (25 mmol/l Tris-phosphate, pH 7.8, 2 mmol/l dithiothreitol, 2 mmol/l EDTA, 10% glycerol and 1% Triton X-100), an aliquot was taken for protein assay. 31 Homogenates were centrifuged at 3000 g for 10 min, and the resulting supernatants were further clarified by means of a second centrifugation at Gene Therapy 12 000 g for 5 min. Duplicate enzymatic assays for luciferase activity were performed with 20 l samples of cleared supernatant using a transilluminator LUMAT LB 9501 (Berthold, Wildbad, Germany). A 100 l aliquot of assay reagent (20 mmol/l Tricine, pH 7.8, 1.07 mmol/l (MgCO 3 ) 4 Mg(OH) 2 × 5H 2 O, 2.67 mmol/l MgSO 4 , 0.1 mmol/l EDTA, 33.3 mmol/l dithiothreitol, 270 mol/l coenzyme A, 470 mol/l D-luciferin, and 530 mol/l ATP) was added to each 20 l sample, and light production over a period of 30 s was measured. Background values from samples injected with the PBS vehicle (equivalent to background from lysis reagent) were subtracted and relative light units determined (RLU/ml). Luciferase activity was then converted to RLU/mg protein. Nonmyocardial probes were similarly analyzed.
Histochemical assay for ␤-galactosidase
The remaining half-cores (see above) were cut into 5 mmthick slices and fixed in ice-cold 2% paraformaldehyde for 16 h. Then each slice was placed in 30% sucrose twice for 12 h. For histological assessment of ␤-galactosidase, the samples were suspended in tissue-freezing medium and snap-frozen in a bath of isopentane cooled by liquid nitrogen. Cryostat sections (15 m thick) were collected on Super-Frost slides (Menzel, Braunschweig, Germany), and washed for 5 min with PBS. The tissue sections were rinsed and incubated for 4 h in a buffered solution of Xgal chromagen (3.5 ml 40 mg/l 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranosidase (X-gal), 1 ml 1 mol/l K 3 Fe(CN) 6 , 2 ml 0.5 mol/l K 4 Fe(CN) 6 and 100 l 1 mol/l MgCl 2 ), then washed again twice with PBS. For histological assessment of ␤-galactosidase activity, two transmural sections (15 m thick) were examined by light microscopy for every half-core. For semiquantitative assessment of positively staining cardiomyocytes, halfcores of the LAD region corresponding to probes with high luciferase activity were consecutively cut into 15 m sections. Ten contiguous fields of 20 sections were analyzed by counting the total number of positive and negative cardiomyocytes in each field (126× magnification) thereby estimating the percentage of ␤-galactosidasepositive cardiomyocytes.
Immunohistochemistry
For immunohistochemistry, transmural tissue samples were taken immediately post-mortem and placed in icecold PBS. Cryostat sections (10 m thick) were collected on special slides (Super-Frost, Menzel), which were then incubated at room temperature with rabbit anti-human T cell CD3 antibody (Dako, Glostrup, Denmark; 0.5 mg/ml protein, 1:100) followed by monoclonal mouse anti-rabbit Ig antibody (Dako; 80 g/ml, 1:25). Anti-alkaline phosphatase was used as detection system and New Fuchsin for staining.
PCR
In order to detect adenoviral transfection total DNA of two animals from each group was extracted from myocardial and nonmyocardial probes (QIAamp-tissue kit; Quiagen, Hilden, Germany). PCR of several tissues (myocardium, skeletal muscle, liver, lung, brain) was performed using 4 g of DNA as a template. 13 Semiquantitative assessment of adenovirus amplification signal was obtained by amplification of titrated amounts of Addel324DNA.
Statistics
All values are given as mean ± s.e.m. Measurements of luciferase activity were analyzed by nonparametric methods (Kruskal-Wallis test and Wilcoxon signed rank test) because the data did not follow a normal distribution. A P value below 0.05 was considered to be statistically significant.
